Loading
Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not.
Dean Fennell (University of Leicester) was chief investigator of CONFIRM, the first placebo-controlled trial to show a survival benefit for a checkpoint inhibitor (nivolumab) in relapsed mesothelioma, and of MARS 2, which showed extended pleurectomy decortication worsens survival and quality of life compared with chemotherapy alone, ending routine radical surgery. He leads the MEDUSA mesothelioma evolution programme.
| Title | Journal | Year |
|---|---|---|
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM) | Lancet Oncology | 2021 |
| Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2) | Lancet Respiratory Medicine | 2024 |
Shares Mesothelioma, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares Mesothelioma, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares MARS 2, Mesothelioma.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Immune checkpoint inhibitors and the tags immunotherapy, surgery.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.